Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
43rd Annual Fall Clinical Dermatology Conference
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension study ADjoin which showed patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing. Results from ADjoin will be presented at the 43rd Annual Fall Clinical Dermatology Conference happening from 19th-22nd October in Las Vegas, Nevada.1
“These results from the ADjoin study provide new hope for patients with moderate-to-severe atopic dermatitis. The fact that the monthly maintenance dose of lebrikizumab can help nearly 80% of individuals maintain clear or almost clear skin for two years is truly promising. This breakthrough not only provides a potential long-term solution for patients, but also relief from the distressing symptoms they suffer from. It is a significant step forward in improving the lives and overall wellbeing of people living with this challenging disease despite the use of topical therapies,” said Prof. Dr. med. Diamant Thaçi, Prof. Dr. med. Diamant Thaçi, Director at the Institute and Comprehensive Centre for Inflammation Medicine, in Lübeck, Germany.
Lebrikizumab is an interleukin-13 (IL-13) inhibitor that specifically blocks IL-13 signaling.2,3,4 The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6
ADjoin is the two-year extension of the lebrikizumab monotherapy trials ADvocate 1 and ADvocate 2 and ADhere, the combination trial with topical corticosteroids. Patients taking lebrikizumab who achieved IGA 0,1 or EASI-75 at 16 weeks in ADvocate 1 and 2 and ADhere were enrolled in ADjoin. Patients in the long-term extension trial received either lebrikizumab 250 mg every two weeks or monthly.1
In ADjoin, lebrikizumab provided durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing.1
Efficacy Outcomes of Patients Entering Long-Term Extension Trial ADjoin
ADvocate 1&2 —> ADjoin
ADhere —> ADjoin
Every two weeks
Every two weeks
Pruritus NRS (Itch) ≥ 4-point improvement
* Data through 68 weeks for Pruritus NRS ≥4-point improvement for ADhere —> ADjoin study; data through 104 weeks for all other outcomes
EASI=Eczema Area and Severity Index; EASI 75=at least 75% improvement from baseline in EASI; EASI 90=at least 90% improvement from baseline in EASI; IGA=Investigator’s Global Assessment; IGA (0,1)=IGA response of clear or almost clear; NRS=numeric rating scale; Q2W=every 2 weeks; Q4W=every 4 weeks (monthly)
The safety profile of lebrikizumab in ADjoin was consistent with previous lebrikizumab studies in patients with moderate-to-severe atopic dermatitis, and no new safety signals were observed up to two years of treatment. In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity. The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster). Less than three percent of patients experienced AEs leading to treatment discontinuation.1
“The two-year data from the ADjoin study further validate the promising efficacy and safety profile of lebrikizumab in people with moderate-to-severe atopic dermatitis. These results demonstrate that monthly maintenance dosing of lebrikizumab provides long-lasting relief from the distressing symptoms of this chronic disease, bringing us one step closer to offering a first-line biologic treatment option,” said Karl Ziegelbauer, Ph.D., Chief Scientific Officer at Almirall.
The two-year long-term extension data build on the positive one-year results previously published in British Journal of Dermatologyas well as the 16-week monotherapy data published in The New England Journal of Medicine. An additional 18 abstracts related to the lebrikizumab development program are being presented at the Fall Clinical Dermatology Conference that further explore key topics affecting patients with atopic dermatitis including key learnings from an exploratory analysis on lebrikizumab speed of response, itch-free days and stability of itch.
“Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials. These data also further our understanding of the long-lasting benefits of lebrikizumab as a potential first-line biologic treatment for patients,” said Lotus Mallbris, M.D., Ph.D., senior vice president of global immunology development and medical affairs at Eli Lilly and Company.
Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.
ADjoin (NCT04392154) evaluated the efficacy and safety of lebrikizumab treatment for two years. Patients taking lebrikizumab who achieved IGA 0,1 or EASI-75 at 16 weeks in ADvocate 1 and 2 and ADhere were enrolled in ADjoin. Patients in the long-term extension trial received either lebrikizumab 250-mg every two weeks or monthly.1
About lebrikizumab and Clinical Development Program
Lebrikizumab is an investigational, monoclonal antibody that binds IL-13 to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13.2-4 The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6
The lebrikizumab phase III program consists of five key global studies evaluating over 1,300 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), as well as long-term extension (ADjoin) and adolescent open label (ADore) studies.
Almirall is a global biopharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patients' needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has focused intensely on patients' needs. Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenue in 2022 was €878.5MM.
For more information, please visit www.almirall.com.
This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.
1 Guttman-Yassky E, et al. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. 2023 Fall Clinical Dermatology Conference. 20 October, 2023.
2 Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017.
3 Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7.
4 Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.1016/j.jmb.2013.01.024.
5 Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954
6 Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media contact Almirall
Phone: (+34) 600 430 581
Investors’ Relations contact
Pablo Divasson del Fraile
Phone: (+34) 93 291 3087
Corporate Communications contact
Phone: (+34) 659 614 173
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global donors pledge over US$777 million to defeat neglected tropical diseases and improve the lives of 1.6 billion people at the Reaching the Last Mile Forum at COP283.12.2023 15:40:00 CET | Press release
Global donors at the 2023 Reaching the Last Mile Forum today pledged a collective US$777.2 million to help control, eliminate, and eradicate neglected tropical diseases (NTDs), in a landmark push to accelerate progress towards achieving the goals outlined in the World Health Organization’s 2030 roadmap on NTDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231203773888/en/ Uniting efforts with NTD-endemic countries, donors answered the urgent call to step up the fight against NTDs in the face of climate change, and to work together to improve the lives of the 1.6 billion people worldwide affected by these devastating yet preventable diseases. The pledging event was hosted by Reaching the Last Mile (RLM), the global health initiative driven by the philanthropy of His Highness Sheikh Mohamed Bin Zayed Al Nahyan, President of the UAE, in partnership with the Bill & Melinda Gates Foundation. The forum took place on the first ev
Sharjah Celebrates the UAE’s 52nd Union Day3.12.2023 09:22:00 CET | Press release
Sharjah concluded the 52nd Union Day celebrations, which lasted for 12 days, with wide participation from all segments of society including government entities, private sector institutions, Emiratis, international residents, and visitors to the emirate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231203827502/en/ From the Union Day celebration in Sharjah (Photo 1: AETOSWire) Over 200 activities organized by the Sharjah National Day Celebrations Committee took place in the cities of Sharjah, Mleiha, Dibba Al Hosn, Khorfakkan, Kalba, Al Bataeh, Al Mudam, Al Dhaid, and Al Hamriyah. Celebrations also took place in cultural and tourist areas as Al Dhaid Fort, the heritage villages in Al Hamriyah, Mleiha, Kalba. Other locations included Wadi Al Hilo, the National Park in Sharjah, Al Hosn Island Canal, Khorfakkan Amphitheatre, Kalba Lake, and Al Bataeh Public Park. His Excellency Khalid Jasim Al Midfa, Chairman of the Sharjah Na
IFRC-DREF calls on global donors to help the world ‘Stand Tall’ in the face of accelerating humanitarian need - supporting smarter and faster disaster relief3.12.2023 01:01:00 CET | Press release
The International Federation of Red Cross and Red Crescent Societies (IFRC) has launched a new campaign to address rapidly escalating climate driven humanitarian crises. It calls on global governments and international donors to support local emergency responders and disaster hit communities - helping them to Stand Tall with smarter and faster humanitarian funding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231202510555/en/ Stand Tall in the face of disaster with IFRC-DREF Insurance. (Photo: Business Wire) The IFRC’s Disaster Response Emergency Fund (IFRC-DREF) is the quickest, most efficient and most transparent way of getting funding directly to local National Societies — both before and immediately after a crisis hits. Yet it faces growing pressure to anticipate and respond to multiple, simultaneous and complex crises around the world as a result of climate change. Today, 3.6 billion people live in areas highly suscep
11 Winners Recognised at Zayed Sustainability Prize Awards Ceremony held during COP28 UAE2.12.2023 03:15:00 CET | Press release
His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, today awarded the winners of the Zayed Sustainability Prize, the UAE’s pioneering global award in sustainability and humanitarianism, during a ceremony held at COP28 UAE in Expo City Dubai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201649250/en/ 11 winners of the Zayed Sustainability Prize Recognised at COP28 (Photo: AETOSWire) The Ceremony was attended by numerous heads of delegations participating in COP28, ministers, senior government officials, and Prize winners and finalists. His Highness congratulated the winners, praising their efforts in promoting sustainability and encouraging them to continue their important contributions in this field. His Highness emphasised that the UAE is steadfast in building upon its established legacy in sustainability, a foundation laid by the country’s Founding Father, the late Sheikh Zayed bin Sultan Al Nahyan.
Zextras Introduces Carbonio - A Private Digital Workplace1.12.2023 16:07:00 CET | Press release
Zextras, the leading email and collaboration solutions provider, introduced Carbonio - a private digital workplace for the public sector and regulated industries. Carbonio emerges as an exceptional solution for the public sector, enabling them to implement an extensive digital workspace for their internal teams and stakeholders. Delivering a suite of features that are not only comprehensive but also fully customizable, from emails and calendars to video meetings and file storage, Carbonio allows for superior adaptation to any unique technical requirements or business objectives. It is equally enticing for regulated industries to enhance their operations by providing secure software solutions tailored to meet the distinct security needs of their country and respective states. The platform is rooted in robust compliance with global data protection regulations, including the European General Data Protection Regulation (GDPR). This fosters a secure digital environment for users, ensuring t